Skip to main content
. 2019 Feb 14;11:1525–1532. doi: 10.2147/CMAR.S191499

Figure 3.

Figure 3

Frequency of grade ≥3 AEs, including hand-foot syndrome (A), weight loss (B), hypocalcemia (C), hypertension (D), nausea (E), and elevated ALT (F), among sorafenib and lenvatinib.

Note: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 indicate statistical significance.

Abbreviations: AEs, adverse effects; ALT, alanine aminotransferase.